CVS Health Corporation $CVS Shares Sold by M&T Bank Corp

M&T Bank Corp cut its holdings in shares of CVS Health Corporation (NYSE:CVS) by 87.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,311 shares of the pharmacy operator’s stock after selling 120,514 shares during the quarter. M&T Bank Corp’s holdings in CVS Health were worth $1,374,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of CVS. Harbor Capital Advisors Inc. increased its position in shares of CVS Health by 72.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 142 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 281 shares during the last quarter. Corundum Trust Company INC purchased a new stake in shares of CVS Health in the 3rd quarter valued at approximately $29,000. GoalVest Advisory LLC purchased a new stake in shares of CVS Health in the 4th quarter valued at approximately $32,000. Finally, SOA Wealth Advisors LLC. increased its position in shares of CVS Health by 36.9% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock valued at $37,000 after purchasing an additional 131 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Up 3.4%

CVS stock opened at $83.72 on Thursday. CVS Health Corporation has a one year low of $58.35 and a one year high of $85.15. The stock has a market capitalization of $107.29 billion, a PE ratio of 60.67, a price-to-earnings-growth ratio of 0.82 and a beta of 0.51. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. The company has a fifty day moving average of $76.20 and a 200-day moving average of $77.94.

CVS Health (NYSE:CVS) last released its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, topping the consensus estimate of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The company had revenue of $105.69 billion during the quarter, compared to analysts’ expectations of $103.67 billion. During the same quarter last year, the business earned $1.19 EPS. The business’s revenue was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, analysts expect that CVS Health Corporation will post 7.14 EPS for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, May 4th. Investors of record on Thursday, April 23rd will be paid a $0.665 dividend. The ex-dividend date is Thursday, April 23rd. This represents a $2.66 annualized dividend and a dividend yield of 3.2%. CVS Health’s dividend payout ratio (DPR) is 192.75%.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS won industry awards for enterprise and customer?experience AI, highlighting scalable AI use across retail and healthcare operations — a signal to investors that technology could drive efficiency and customer engagement gains. CVS Health’s Award Winning AI Raises Questions For Investors To Watch
• Positive Sentiment: CVS launched an AI health platform in partnership with Google Cloud, which may accelerate product rollouts, data analytics, and customer?facing services — a strategic tie that supports long?term margin and service improvements. CVS launches AI health platform with Google Cloud partnership
• Positive Sentiment: Options and flow data show heavy call buying and unusual call activity ahead of CVS’s May earnings, indicating some investors are positioning bullishly for the outlook or guidance cadence. This can amplify upside moves into the report. Unusual Call Option Activity in CVS Ahead of Its Earnings Shows Investors are Bullish
• Positive Sentiment: CVS revamped its loyalty program with a two?tier structure, which could improve customer retention and same?store economics at retail pharmacies over time. CVS revamps loyalty program with two-tiered benefits
• Positive Sentiment: Sector tailwinds: CMS finalized a Medicare Advantage/Part D rate update that was better than feared for 2027, which supports Aetna’s medium?term revenue outlook; CVS has previously reiterated mid?term EPS targets and guidance that investors are watching. CVS rises as investors focus on earnings outlook and Medicare Advantage tailwinds
• Neutral Sentiment: Investor interest has spiked (search and attention metrics), and recent analyst coverage shows a cluster of buy/overweight ratings and mid?$90s median price targets — supportive background but not new fundamental catalysts. Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
• Neutral Sentiment: Corporate hires and security leadership changes were announced (new security chief), a routine governance update with limited immediate revenue impact. CVS taps former Sutter Health executive as security chief
• Negative Sentiment: Analysts expect a decline in near?term earnings for the upcoming quarter, and Zacks previews suggest CVS may lack the mix for an earnings beat — a potential headwind that could cap upside if the print confirms weaker margins or PBM dynamics. Analysts Estimate CVS Health (CVS) to Report a Decline in Earnings: What to Look Out for

Wall Street Analyst Weigh In

A number of brokerages have commented on CVS. Wolfe Research dropped their price objective on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. Bank of America dropped their price objective on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating on the stock in a research report on Tuesday, January 27th. Robert W. Baird increased their price objective on shares of CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Argus dropped their target price on shares of CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, January 28th. Finally, The Goldman Sachs Group increased their target price on shares of CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research report on Thursday, February 12th. Twenty equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $95.05.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.